Phase II study of teniposide in adenocarcinoma of the lung

A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting si...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1991-01, Vol.27 (6), p.487-489
Main Authors: SOÊRENSEN, J. B, BACH, F, DOMBERNOWSKY, P, HANSEN, H
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adult
Aged
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Drug Administration Schedule
Drug Evaluation
Female
Humans
Leukopenia - chemically induced
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Remission Induction
Teniposide - administration & dosage
Teniposide - adverse effects
Teniposide - therapeutic use
Thrombocytopenia - chemically induced
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC counts of less than 2 x 10(9)/l being observed in 42% of patients, resulting in one septic death. At the dose and schedule used in the present study, teniposide showed only limited activity in adenocarcinoma of the lung.
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00685166